AstraZeneca Aktie 163523 / US0463531089
69.59
USD
-1.53
USD
-2.15 %
03.07.2025
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
AstraZeneca Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | AstraZeneca PLC (spons. ADRs) | 2.32 | 1.52 | USD |
| 2023 | AstraZeneca PLC (spons. ADRs) | 2.11 | 1.42 | USD |
| 2022 | AstraZeneca PLC (spons. ADRs) | 2.09 | 1.42 | USD |
| 2021 | AstraZeneca PLC (spons. ADRs) | 2.41 | 1.41 | USD |
| 2020 | AstraZeneca PLC (spons. ADRs) | 2.74 | 1.37 | USD |
| 2019 | AstraZeneca PLC (spons. ADRs) | 2.75 | 1.37 | USD |
| 2018 | AstraZeneca PLC (spons. ADRs) | 3.61 | 1.37 | USD |
| 2017 | AstraZeneca PLC (spons. ADRs) | 3.95 | 1.37 | USD |
| 2016 | AstraZeneca PLC (spons. ADRs) | 5.01 | 1.37 | USD |
| 2015 | AstraZeneca PLC (spons. ADRs) | 4.04 | 1.37 | USD |
Gewinn je Aktie- AstraZeneca
| 2.3 24 | 1.9 23 | 1.1 22 | 0.0 21 | 1.2 20 | 0.5 19 | 0.8 18 |
Umsatz je Aktie- AstraZeneca
| 17.3 24 | 14.7 23 | 14.2 22 | 13.3 21 | 10.5 20 | 9.4 19 | 8.7 18 |
KGV- AstraZeneca
| 28.9 24 | 35.0 23 | 63.8 22 | 1475 21 | 41.0 20 | 97.2 19 | 44.7 18 |
AstraZeneca PLC (spons. ADRs): Die Aktie (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 2.27 | 1.92 | 1.06 | 0.04 | 1.22 | 0.52 | 0.85 |
| Gewinn je Aktie (unverwässert) | 2.27 | 1.92 | 1.06 | 0.04 | 1.22 | 0.51 | 0.85 |
| Gewinn je Aktie (verwässert) | 2.25 | 1.91 | 1.05 | 0.04 | 1.22 | 0.51 | 0.85 |
| Dividende je Aktie | 1.52 | 1.42 | 1.42 | 1.41 | 1.37 | 1.37 | 1.37 |
| Veränderung Dividende je Aktie in % | 7.04 | 0.00 | 1.07 | 2.55 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 4’629.00 | 4’481.00 | 4’364.00 | 3’856.00 | 3’572.00 | 3’592.00 | 3’484.00 |
AstraZeneca PLC (spons. ADRs): Unternehmenskennzahlen (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 17.30 | 14.66 | 14.22 | 13.26 | 10.51 | 9.37 | 8.72 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 28.87 | 35.04 | 63.84 | 1’474.68 | 41.04 | 97.17 | 44.66 |
| KGV (Jahresendkurs, Gewinn verwässert) | 29.11 | 35.33 | 64.34 | 1’485.97 | 41.07 | 97.17 | 44.66 |
| Dividendenrendite Jahresende in % | 2.32 | 2.11 | 2.09 | 2.41 | 2.74 | 2.75 | 3.61 |
| Eigenkapitalquote in % | 39.29 | 38.73 | 38.41 | 37.29 | 23.44 | 23.78 | 23.16 |
| Fremdkapitalquote in % | 60.71 | 61.27 | 61.59 | 62.71 | 76.56 | 76.22 | 76.84 |
AstraZeneca PLC (spons. ADRs): GuV (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 54’073.00 | 45’811.00 | 44’351.00 | 37’833.00 | 27’594.00 | 24’384.00 | 22’090.00 |
| Umsatzveränderung in % | 18.03 | 3.29 | 17.23 | 37.11 | 13.16 | 10.38 | -1.67 |
| Bruttoergebnis vom Umsatz | 40’545.00 | 33’877.00 | 28’102.00 | 23’041.00 | 20’422.00 | 17’642.00 | 15’856.00 |
| Bruttoergebnisveränderung in % | 19.68 | 20.55 | 21.97 | 12.82 | 15.76 | 11.26 | -4.76 |
| Operatives Ergebnis | 12’789.00 | 9’411.00 | 5’060.00 | 2’864.00 | 4’685.00 | 2’807.00 | 1’836.00 |
| Veränderung Operatives Ergebnis in % | 35.89 | 85.99 | 76.68 | -38.87 | 66.90 | 52.89 | -47.10 |
| Ergebnis vor Steuern | 8’719.00 | 6’911.00 | 2’506.00 | -201.00 | 3’943.00 | 1’664.00 | 2’106.00 |
| Veränderung Ergebnis vor Steuern in % | 26.16 | 175.78 | - | - | 136.96 | -20.99 | -7.71 |
| Ergebnis nach Steuer | 7’035.00 | 5’955.00 | 3’288.00 | 112.00 | 3’196.00 | 1’335.00 | 2’155.00 |
| Veränderung Ergebnis nach Steuer in % | 18.14 | 81.11 | 2’835.71 | -96.50 | 139.40 | -38.05 | -28.19 |
AstraZeneca PLC (spons. ADRs): Bilanz (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 63’164 | 61’953 | 59’425 | 66’076 | 51’091 | 46’781 | 46’607 |
| Langzeit Gesamtverbindlichk. je Aktie | - | - | - | - | 11.73 | 10.92 | 11.96 |
| Eigenkapital | 40’871 | 39’166 | 37’058 | 39’287 | 15’638 | 14’596 | 14’044 |
| Veränderung Eigenkapital in % | 4.20 | 5.69 | -5.68 | 151.36 | 19.01 | 5.29 | -16.66 |
| Bilanzsumme | 104’035 | 101’119 | 96’483 | 105’363 | 66’729 | 61’377 | 60’651 |
| Veränderung Bilanzsumme in % | 2.88 | 4.80 | -8.43 | 57.90 | 8.72 | 1.20 | -4.27 |
AstraZeneca PLC (spons. ADRs): Sonstige Angaben (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 2.27 | 1.92 | 1.06 | 0.04 | 1.22 | 0.51 | 0.85 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 18.06 | 81.00 | 2’588.61 | -96.76 | 137.38 | -39.66 | -28.24 |
| Gewinn je Aktie (verwässert) | 2.25 | 1.91 | 1.05 | 0.04 | 1.22 | 0.51 | 0.85 |
| Veränderung Gewinn je Aktie (verwässert) in % | 18.06 | 80.89 | 2’588.27 | -96.78 | 137.21 | -39.66 | -28.24 |
| Anzahl Mitarbeiter | 94’300 | 89’900 | 83’500 | 83’100 | 76’100 | 70’600 | 64’400 |
| Veränderung Anzahl Mitarbeiter in % | 4.89 | 7.66 | 0.48 | 9.20 | 7.79 | 9.63 | 5.40 |
AstraZeneca PLC (spons. ADRs) Termine
| Unternehmen | Event | Datum |
|---|---|---|
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 29.07.2025 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 06.11.2025 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 05.02.2026 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 24.04.2026 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 23.07.2026 |
AstraZeneca PLC (spons. ADRs) vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q1 2025 Earnings Release | 29.04.2025 |
| Hauptversammlung | Annual General Meeting | 11.04.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 06.02.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 12.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 25.07.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 25.04.2024 |
| Hauptversammlung | Annual General Meeting | 11.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 08.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 09.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 28.07.2023 |
| Hauptversammlung | Annual General Meeting | 27.04.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 09.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 10.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 29.07.2022 |
| Hauptversammlung | Annual General Meeting | 29.04.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 29.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 10.02.2022 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 64’400 | 70’600 | 76’100 | 83’100 | 83’500 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.34 | 0.35 | 0.36 | 0.46 | 0.53 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 15’518 | 15’563 | 19’544 | 26’244 | 22’593 |
| Summe Anlagevermögen | 45’133 | 45’814 | 47’185 | 79’119 | 73’890 |
| Summe Aktiva | 60’651 | 61’377 | 66’729 | 105’363 | 96’483 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 46’607 | 46’781 | 51’091 | 66’076 | 59’425 |
| Summe Eigenkapital | 14’044 | 14’596 | 15’638 | 39’287 | 37’058 |
| Summe Passiva | 60’651 | 61’377 | 66’729 | 105’363 | 96’483 |
Adresse
| Cambridge Biomedical Campus, CB2 0AA Cambridge | |
| Telefon | +44 (20) 3749-5000 |
| URL | http://www.astrazeneca.com |
Management
|
Alberto Hegewisch
Chief Medical Officer |
|
Amy E. McKee
Senior Vice President-Oncology Regulatory Science |
|
Andy Barnett
Head-Investor Relations |
|
Anna Olive Magdelene Manz
Non-Executive Director |
|
Aradhana Sarin
Chief Financial Officer & Executive Director |
|
Birgit Conix
Non-Executive Director |
|
Cindy L. Hoots
Chief Digital & Information Officer |
|
Dafni Bika
SVP & Global Head-Pharmaceutical Technology |
|
David Fredrickson
Executive Vice President-Oncology Business Unit |
|
Diana Layfield
Non-Executive Director |
|
Euan A. Ashley
Non-Executive Director |
|
Helen MacPhee
Vice President |
|
Iskra Reic
Executive Vice President-International Operations |
|
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel |
|
Jonathan Thomas Charles Slade
Group Treasurer |
|
Karen E. Knudsen
Non-Executive Director |
|
Kevin G. Lokay
Head-Change Implementation |
|
Marc Pierre Jean Dunoyer
Chief Strategy Officer |
|
Marcus Wallenberg
Independent Non-Executive Director |
|
Margareta Elisabeth Björk
Senior VP & Head-Late Stage Development |
|
Matthew Shaun Bowden
Secretary |
|
Michel Demaré
Non-Executive Chairman |
|
Nazneen Rahman
Independent Non-Executive Director |
|
Pam P. Cheng
Executive VP-Operations & Information Technology |
|
Pascal Soriot
Chief Executive Officer & Executive Director |
|
Philip Arthur John Broadley
Senior Independent Non-Executive Director |
|
Regina Fritsche-Danielson
SVP, Head-Research & Early Development |
|
Rene Anthony Andrada Haas
Non-Executive Director |
|
Ruud Dobber
Executive VP-Biopharmaceuticals Business |
|
Sharon Barr
EVP-BioPharmaceuticals Research & Development |
|
Sherilyn D. McCoy
Independent Non-Executive Director |
|
Shu Kam Mok
Independent Non-Executive Director |
|
Sjoerd Hubben
Vice President-Global Government Affairs & Policy |
|
Susan Mary Galbraith
Executive VP-Oncology Research & Development |
|
Tyrell J. Rivers
Executive Director-Corporate Development |